LY3462817 (SC) for Healthy Subjects (HS)
Phase-Based Progress Estimates
Effectiveness
Safety
Altasciences Clinical Los Angeles, Inc, Cypress, CA
Healthy Subjects (HS)
LY3462817 (SC) - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3462817 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3462817 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 12 weeks.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: Predose on Day 1 through Day 85
Baseline through Week 12
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Day 85
PK: Maximum Concentration (Cmax) of LY3462817
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3462817
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
LY3462817 - SC
1 of 4
LY3462817 - IV
1 of 4
Placebo - SC
1 of 4
Placebo - IV
1 of 4
Experimental Treatment
Non-Treatment Group
32 Total Participants · 4 Treatment Groups
Primary Treatment: LY3462817 (SC) · Has Placebo Group · Phase 1
LY3462817 - SC
Drug
Experimental Group · 1 Intervention: LY3462817 (SC) · Intervention Types: DrugLY3462817 - IV
Drug
Experimental Group · 1 Intervention: LY3462817 (IV) · Intervention Types: DrugPlacebo - SC
Drug
PlaceboComparator Group · 1 Intervention: Placebo (SC) · Intervention Types: DrugPlacebo - IV
Drug
PlaceboComparator Group · 1 Intervention: Placebo (IV) · Intervention Types: DrugTrial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: predose on day 1 through day 85
Closest Location: Altasciences Clinical Los Angeles, Inc · Cypress, CA
2022First Recorded Clinical Trial
6 TrialsResearching Healthy Subjects (HS)
2 CompletedClinical Trials
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,427 Previous Clinical Trials
3,102,411 Total Patients Enrolled
313 Trials studying Healthy Subjects (HS)
15,791 Patients Enrolled for Healthy Subjects (HS)
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,231 Previous Clinical Trials
364,026 Total Patients Enrolled
272 Trials studying Healthy Subjects (HS)
13,339 Patients Enrolled for Healthy Subjects (HS)
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have no medical conditions that would preclude you from participating in the study.
You are a non-Japanese participant.
You are of childbearing potential.
You have the necessary medical and psychological conditions for the study.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments